Valneva SE (VALN) announced that Health Canada has approved IXCHIQ, the company's single-dose vaccine for the prevention of disease caused by the chikungunya virus in individuals 18 years of age and older. IXCHIQ is the world's only licensed chikungunya vaccine.
Valneva began commercializing the vaccine in the U.S. in the current year. It plans to sell first doses in Canada in the fourth quarter of 2024. The European Medicines Agency recently recommended marketing authorization of the vaccine in Europe, and a formal decision is expected in the third quarter of 2024.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.